NCT00057304View on ClinicalTrials.gov

Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions
Diabetes
Interventions
DRUG

RO 205-2349

Trial Locations (46)

1100

Craiova

1217

Meyrin

1233

Sofia

1431

Sofia

1606

Sofia

2000

Ploieşti

2900

Arad

4002

Plovdiv

4300

Târgu Mureş

5800

Pleven

6200

Galati

7000

Bucharest

10138

Tallinn

17011

Camp Hill

23451

Virginia Beach

24266

Lebanon

27560

Morrisville

27710

Durham

29651

Greer

33021

Hollywood

38119

Memphis

38163

Memphis

42039

Pachuca, Hidalgo

44340

Guadalajara, JAL.

44349

Guadalajara

50406

Tartu

50708

Tartu

64320

Monterrey

64410

Monterrey

64460

Monterrey

65609

Võru

75230

Dallas

77030

Houston

79705

Midland

97000

Mérida

97219

Portland

97239

Portland

500326

Brasov

Unknown

Chihuahua, Chih.

Panama City

06700

Mexico City

00732-7994

Ponce

020475

Bucharest

0200

Târgovişte

RG12 1HX

Bracknell

NG2 3HF

Nottingham

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00057304 - Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter